Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach

被引:2
|
作者
Qi, Hongchao [1 ,2 ,3 ]
Rizopoulos, Dimitris [1 ,2 ]
van Rosmalen, Joost [1 ,2 ]
机构
[1] Erasmus Univ, Med Ctr, Dept Biostat, Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands
[3] Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
关键词
Bayesian statistics; dynamic borrowing; meta-analytic-predictive; sample size calculation; PEDIATRIC LIVER-TRANSPLANTATION; NETWORK METAANALYSIS; MACULAR DEGENERATION; PRIOR DISTRIBUTIONS; IMMUNOSUPPRESSION; RANIBIZUMAB; DESIGN; AFLIBERCEPT; INFORMATION; SIMULATION;
D O I
10.1002/jrsm.1618
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The meta-analytic-predictive (MAP) approach is a Bayesian method to incorporate historical controls in new trials that aims to increase the statistical power and reduce the required sample size. Here we investigate how to calculate the sample size of the new trial when historical data is available, and the MAP approach is used in the analysis. In previous applications of the MAP approach, the prior effective sample size (ESS) acted as a metric to quantify the number of subjects the historical information is worth. However, the validity of using the prior ESS in sample size calculation (i.e., reducing the number of randomized controls by the derived prior ESS) is questionable, because different approaches may yield different values for prior ESS. In this work, we propose a straightforward Monte Carlo approach to calculate the sample size that achieves the desired power in the new trial given available historical controls. To make full use of the available historical information to simulate the new trial data, the control parameters are not taken as a point estimate but sampled from the MAP prior. These sampled control parameters and the MAP prior based on the historical data are then used to derive the statistical power for the treatment effect and the resulting required sample size. The proposed sample size calculation approach is illustrated with real-life data sets with different outcomes from three studies. The results show that this approach to calculating the required sample size for the MAP analysis is straightforward and generic.
引用
收藏
页码:396 / 413
页数:18
相关论文
共 50 条
  • [21] Sample size calculation for complex clinical trials with survival endpoints
    Shih, JH
    [J]. CONTROLLED CLINICAL TRIALS, 1995, 16 (06): : 395 - 407
  • [22] Sample size calculation for clinical trials: the impact of clinician beliefs
    Fayers, PM
    Cuschieri, A
    Fielding, J
    Craven, J
    Uscinska, B
    Freedman, LS
    [J]. BRITISH JOURNAL OF CANCER, 2000, 82 (01) : 213 - 219
  • [24] On sample size calculation in bioequivalence trials
    Chow, SC
    Wang, HS
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (02) : 155 - 169
  • [25] On Sample Size Calculation in Bioequivalence Trials
    Shein-Chung Chow
    Hansheng Wang
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28 : 155 - 169
  • [26] Sample Size Calculation When Planning Clinical Trials with Intercurrent Events
    Yixin Fang
    Man Jin
    [J]. Therapeutic Innovation & Regulatory Science, 2021, 55 : 779 - 785
  • [27] Sample Size Calculation When Planning Clinical Trials with Intercurrent Events
    Fang, Yixin
    Jin, Man
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (04) : 779 - 785
  • [28] Sample size calculation for the augmented logrank test in randomized clinical trials
    Hattori, Satoshi
    Komukai, Sho
    Friede, Tim
    [J]. STATISTICS IN MEDICINE, 2022, 41 (14) : 2627 - 2644
  • [29] THE QUALITY OF SAMPLE SIZE CALCULATION (SSC) REPORTING IN CANCER CLINICAL TRIALS
    Bariani, G. M.
    Ferrari, A. C. R. C.
    Hoff, P. M.
    Arai, R.
    Precivale, M.
    Riechelmann, R. P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 450 - 450
  • [30] Sample size for clinical trials
    Billings, M.
    Lopez Mitnik, G.
    Dye, B. A.
    [J]. ORAL DISEASES, 2017, 23 (08) : 1013 - 1018